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Predictors of Patency after Balloon Angioplasty in
Hemodialysis Fistulas: A Systematic Review
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Angela C. Webster, MBBS, MMed (Clin Epi), PhD, MRCP, FRACP,
Richard A. Baer, BPharm, MBBS (Hons), FRACP, Jonathan Golledge, BA, MB,
BChir, MChir, FRCS, FRACS, and Murty L. Mantha, MD, FRACPABSTRACT
Percutaneous transluminal angioplasty (PTA) is an established treatment for dysfunctional hemodialysis fistulas. This article
systematically reviews evidence for predictors of patency after PTA. Outcomes assessed were primary, assisted primary, and
secondary patency after intervention, and findings were summarized descriptively. This review included 11 nonrandomized
observational studies of 965 fistulas in 939 patients. Follow-up ranged from 0 days to 10 years. Study quality was overall
suboptimal. Newer fistulas and longer lesion length may be associated with primary patency loss after PTA. Further studies are
needed to confirm these findings, to identify potentially modifiable factors, and to guide the testing of new endovascular devices.
ABBREVIATIONS
AVF = arteriovenous fistula, HbA1c = glycosylated hemoglobin, HR = hazard ratio, RR = relative riskOne of the greatest challenges of hemodialysis is the
limited durability of vascular access. Access-related
complications are a common cause of hospital admission
in patients undergoing hemodialysis (1). In the United
States, the cost of managing access dysfunction is& SIR, 2014
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Neointimal hyperplasia is the most common cause of
access dysfunction in both autogenous (native arterio-
venous fistulas [AVFs]) and nonautogenous (prosthe-
tic grafts) arteriovenous access (3). In native AVFs,
although perianastomotic stenosis is most common,
neointimal hyperplasia often occurs through the access
circuit, particularly at the cephalic arch (4). Percutan-
eous transluminal angioplasty (PTA) is an establi-
shed treatment for stenosis in both native AVFs and
prosthetic grafts, but patency after angioplasty is highly
variable. Only 26%–58% of native AVFs remain functio-
nal without subsequent interventions at 12 months (5,6).
Patency in native AVFs after angioplasty depends on
a range of clinical, anatomic, and biochemical factors
(5,7–9). This review systematically summarizes evidence
regarding which risk factors are associated with patency
loss in native AVFs after angioplasty.MATERIALS AND METHODS
Protocol and Focus
This systematic review is reported using the Preferred
Reporting Items for Systematic Reviews and Meta-
Analyses guidelines (10). The review focuses on studies
that assessed predictors of patency after balloon
angioplasty to maintain native AVF function.
Neuen et al ’ JVIR918 ’ Predictors of Patency after PTA in Hemodialysis FistulasSearch Criteria
A literature search was conducted of publications avail-
able up to May 1, 2013, by one investigator. MEDLINE
was searched via OvidSP, using the following terms:
“renal dialysis,” “renal replacement therapy,” and “arte-
riovenous shunt, surgical” and “angioplasty” or “endo-
vascular procedures” or “vascular patency.” Reference
lists of relevant studies were searched by hand to identify
additional publications. One investigator screened the
titles and abstracts of all retrieved citations, and the full
text of potential studies were reviewed where necessary.Eligibility Criteria
Studies that assessed predictors of patency in native
AVFs after PTA were included. Potential predictors of
patency were related to clinical, anatomic, biochemical,
or medication factors. Three patency outcomes were
used in accordance with the Society of Interventional
Radiology (SIR) reporting standards (11). Primary
patency after intervention was defined as the interval
after PTA until repeated percutaneous intervention or
fistula thrombosis. Assisted primary patency after
intervention was defined as the interval after PTA until
fistula thrombosis or surgical intervention that excludes
the treated lesion from the access circuit. Secondary
patency after intervention was defined as the interval
after PTA until the fistula was surgically declotted,
revised, or abandoned.
There were no restrictions on the study size, design, or
language. Studies that separated outcomes for native
AVFs and prosthetic grafts in statistical analysis were
included. We included all relevant publications arising
from observational cohort studies. We included studies
that combined both immature and mature AVFs in
their analyses. We excluded studies focusing solely on
balloon-assisted maturation, defined as angioplasty of
native fistulas that had not been used for dialysis. We
also excluded studies focusing exclusively on percuta-
neous thrombolysis or thrombectomy, studies focusing
on other access types, studies combining endovascular
and open surgical repair, studies using patency defini-
tions different from the SIR reporting standards, or
studies comparing different devices or techniques.Data Extraction and Analysis
One investigator used a standardized data sheet to extract
data from included studies. Data were extracted for total
number of patients and fistulas, fistula location, study
design, inclusion of immature or thrombosed fistulas,
predictors of patency after intervention, and follow-up
duration. Any uncertainty was resolved through consensus
discussion with other authors. A meta-analysis pooling the
association between individual variables and primary
patency after intervention was initially planned; however,
data extracted proved unsuitable for meta-analysis.The reasons for the unsuitability of data are described in
the Results section.
Quality Assessment
We developed a modified tool to assess risk of bias in
included studies. This assessment tool was based on a
validated checklist for nonrandomized studies included
in systematic reviews (12) and the SIR reporting guide-
lines (11). Risk of bias was assessed in seven independent
domains: study design (prospective or retrospective),
statistical analysis (univariate or multivariate), referral
criteria for PTA, complete reporting of all variables to
be assessed and results reported, prior AVF inter-
ventions described, PTA details adequately described,
and description of lesion measurement definitions.RESULTS
Search Results
Database and reference list searching yielded 2,143
articles, of which full text of 27 articles was examined
(Fig). Based on our inclusion and exclusion criteria, we
included 13 reports of 11 studies that involved 965 AVFs
in 939 patients (Table 1). Follow-up ranged from 0 days
to 10 years. All studies were single-center reports with
a small number of patients. Only three studies included
4 100 participants; the largest study comprised 162
participants (Table 1).
Quality Assessment
The quality of studies was overall suboptimal (Table 2).
Of 11 studies, 8 were retrospective in design, and 3 were
prospective. No studies reported how complete their data
were or were explicit about missing data. Of 11 studies, 5
did not perform multivariate analysis to allow for the
combined effects of potential risk factors. These studies
used univariate analysis alone, used the log-rank test to
compare categorical variables, or did not provide enough
information to assess statistical methods adequately.
Eight studies did not report whether previous percuta-
neous interventions had been performed in the AVFs
being investigated. In five studies, predictors of patency
were selectively reported; for example, nonsignificant
variables were not reported, or the study methods did
not define a priori which variables would be assessed.
Four studies included angioplasties in both immature and
mature AVFs. Studies often included patients several
times if they had more than one AVF during the study
period. Current evidence suggests that AVF surveillance
may reduce thrombosis rates (14), but there was
considerable variability in the reporting of referral
criteria and surveillance protocols. All but one study
(comprising 140 participants) converted continuous
measures into categories for analysis (9). In some cases,
multiple different cutoff points for the same measure were
applied in different studies, producing some statistically
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Figure. Flow diagram showing identification of studies for inclusion in a systematic review of factors predicting fistula patency after
angioplasty.
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AVF location and intervention details, were omitted. For
these reasons, we chose to describe our findings
descriptively, rather than perform a meta-analysis.
Primary Patency after Intervention
Of 11 studies, 10 assessed the association of various
anatomic, clinical, biochemical, and medication factors
and primary patency. These studies and their findings
are summarized in Table 3.
Various anatomic characteristics were shown to be
associated with primary patency. In three of seven
studies, it was found that the newer the fistulas were at
the time of angioplasty, the shorter the primary patency.
In two of these studies, fistula age as a continuous
variable was a significant predictor (hazard ratio [HR],
0.97 per month increase, P ¼ .038, and HR not reported,
P ¼ .009) (7,15). One study found that fistulas o 6
months old at angioplasty predicted shorter primary
patency compared with fistulas4 6 months old (relative
risk [RR], 4.52, P = .007) (6). One large study (N ¼ 151)found that upper arm fistulas had shortened primary
patency compared with forearm fistulas (HR, 1.81, P ¼
.005) (8). Although four other studies did not show an
association between fistula location and patency, two of
these studies had much smaller sample sizes (5,15). Two
studies that focused predominately on radiocephalic
fistulas found that longer lesions had shortened primary
patency. One study found that lesions 4 4 cm predicted
primary patency loss (RR, 5.51, P = .004) (6), whereas
the other found that lesions 4 2 cm predicted shorter
primary patency (RR, 7.5, P ¼ .002) (5). Studies that did
not describe fistula location and studies that included a
relatively equal proportion of upper arm and forearm
fistulas reported no association between lesion length
and primary patency. Lesion location, presence of
multiple lesions throughout the access circuit, and
degree of stenosis before and after angioplasty did not
predict primary patency in any of the studies.
In terms of clinical and cardiovascular risk factors,
only diabetes was associated with primary patency loss
in one study (HR, 1.97, P ¼ .04) (9). Seven other studies
Table 2 . Quality Assessment
Author, Year Prospective
Multivariate
Analysis
Indications for
Referral
Assessed Variables
Prespecified*
First Intervention
in AVF
Intervention Details
Adequate†
Lesion Definitions
Described‡
Clark et al, 2002 (5) No Yes Yes No Unknown Yes No
Doi et al, 2008 (17) No No No Yes Unknown No Not applicable
Heerwagen et al, 2012 (15) Yes Yes Yes No Yes Yes No
Heye et al, 2011 (7) No No Yes Yes Yes Yes No
Liu et al, 2007 (16) No Unclear No No Unknown No Not applicable
Maeda et al, 2005 (6) No Yes No Yes Unknown Yes No
Manninen et al, 2001 (20) Yes Yes Yes No Unknown Yes No
Mortamais et al, 2013 (18) No Unclear Yes Yes Unknown Yes No
Rajan et al, 2003 (4), 2004 (8) No Yes Yes Yes Unknown Yes No
Sugimoto et al, 2003 (19) No No Yes Yes Unknown Yes No
Wu et al, 2009 (9), 2010 (13) Yes Yes Yes No No Yes Yes
AVF ¼ arteriovenous fistula.
*Methods clearly state all variables to be assessed, and all variables are reported in results or tables.
†Intervention technique and materials adequately described or referenced.
‡Definitions of lesion length (in cases of multiple lesions) and percentage stenosis adequately described.
Table 1 . Summary of Included Studies
Author, Year No. Patients No. AVFs AVF Location Immature AVFs Included Thrombosed AVFs Included Follow-up (mo)
Clark et al, 2002 (5) 65 65 Forearm and upper arm Yes Yes 6–26
Doi et al, 2008 (17) 54 54 Not reported Unclear Unclear 12
Heerwagen et al, 2012 (15) 61 61 Forearm and upper arm No Unclear 0.7–31.1
Heye et al, 2011 (7) 162 167 Forearm and upper arm Yes No 36
Liu et al, 2007 (16) 82 82 Forearm and upper arm No No 6
Maeda et al, 2005 (6) 59 60 Forearm No Yes 0–51
Manninen et al, 2001 (20) 51 53 Forearm Yes Yes 0.5–67.1
Mortamais et al, 2013 (18) 75 75 Forearm Yes No 1–122
Rajan et al, 2003 (4), 2004 (8) 140 151 Forearm and upper arm No No 0.1–119
Sugimoto et al, 2003 (19) 50 57 Forearm Unclear Yes 12
Wu et al, 2009 (9), 2010 (13) 140 140 Not reported No No 6
AVF ¼ arteriovenous fistula.
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Table 3 . Factors Associated with Primary Patency after Intervention
Author, Year
Mean
Patient
Age (y)
Mean AVF
Age (mo)
Male
(%) DM (%)
Upper Arm
AVF (%)
Lesion Length
Classification
(cm) Other Variables Assessed
Significant Findings and Magnitude of
Effect
Heerwagen et al,
2012 (15)
63 20 66 32 40 o 2 vs 4 2 Lesion location, multiple lesions, stenosis
before and after PTA (%), PVD, vessel
disease score*, blood flow after
intervention, change in blood flow,
previous interventions
AVF age (HR, 0.97 per month increase,
P ¼ .038); previous interventions
(HR, 2.94, P ¼ .008)
Heye et al, 2011 (7) 66 19 62 35 58 Linear Prior AVF, lesion location, multiple
lesions, stenosis before and after PTA
AVF age (HR, per month increase not
reported, P ¼ .01)
Doi et al, 2008 (17) 63 Not
assessed
57 37 Not
assessed
Not assessed Calcium channel blocker, antiplatelet,
angiotensin receptor blocker
Calcium channel blocker (OR, 5.1,
P o .05)
Liu et al, 2007 (16) 62 41 39 45 10 Not assessed Hypertension, total cholesterol,
triglycerides, smoking, calcium,
phosphate, CPP, PTH, URR, albumin,
aspirin
Hypertension (HR not reported); smoking
(HR not reported); URR (RR, 1.05,
P ¼ .009); CPP (RR, 1.22, P ¼ .042);
albumin (RR, 0.32, P ¼ .001)
Maeda et al, 2005
(6)
62 Unreported 75 Unreported 0 o 4 vs 4 4 Total occlusion, multiple lesions, balloon
diameter, duration of dialysis
Lesion length4 4 cm (RR, 5.21, P ¼ .004);
AVF age o 6 mo (RR, 4.52, P ¼ .007)
Rajan et al, 2004 (8) 62 Unreported 74 30 38 Not assessed Multiple lesions Upper arm AVF (HR, 1.81, P ¼ .005)
Clark et al, 2002 (5) 64 24 57 42 28 o 2 vs 4 2, o
5 vs 4 5, o
10 vs 4 10
CAD, PVD, vessel disease score*, lesion
location, stenosis before and after PTA
(%), intervention type
Lesion length 4 2 cm (RR, 7.5, P ¼ .002);
vessel disease score* (RR, 1.6, P ¼ .03)
Sugimoto et al,
2003 (19)
67 Unreported 70 Unreported 0 Long vs short
segment
(not defined)
Multiple lesions, lesion location, total
occlusion
None
Manninen et al,
2001 (20)
59 10.5 57 Not
assessed
100 Linear Lesion location, multiple lesions,
intervention type
None
Wu et al, 2009 (9) 61 Unreported 42 35 Unreported Linear Hypertension, smoking, lesion location,
reference vessel diameter, stenosis
before and after PTA (%), metabolic
markers†, inflammatory markers‡,
creatinine, Kt/V, homocysteine, ADMA,
medications§
ADMA (HR, 2.65, P ¼ .005); DM (HR, 1.97,
P ¼ .04); LDL (HR, 2.29, P ¼ .03); HbA1c
4 7% (log-rank, P ¼ .01) (13)
ADMA ¼ asymmetric dimethylarginine; AVF ¼ arteriovenous fistula; CAD ¼ coronary artery disease; CPP ¼ calcium phosphate product; DM ¼ diabetes mellitus; HbA1c ¼ glycosylated
hemoglobin; HR ¼ hazard ratio; Kt/V ¼ measure of dialysis adequacy; LDL ¼ low-density lipoprotein; OR ¼ odds ratio; PTA ¼ percutaneous transluminal angioplasty; PTH ¼
parathyroid hormone; PVD ¼ peripheral vascular disease; RR ¼ relative risk; URR ¼ urea reduction ratio.
*Composite variable of DM, CAD, and PVD.
†LDL, high-density lipoprotein, triglycerides, calcium, phosphate, albumin, and hemoglobin.
‡High-sensitivity C-reactive protein, interleukin-1β, interkleukin-6, tumor necrosis factor-α, monocyte chemoattractant protein-1, E-selectin, P-selectin, intercellular adhesion molecule-
1, and vascular adhesion molecule-1.
§Antiplatelets, nitrates, beta blockers, calcium channel blockers, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, lipid-lowering agent.
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Neuen et al ’ JVIR922 ’ Predictors of Patency after PTA in Hemodialysis Fistulaswith longer follow-up found no association between
diabetes in primary patency loss. One study found that
a composite of diabetes, coronary artery disease, and
peripheral vascular disease was associated with shorter
primary patency if more than one comorbidity was
present (RR, 1.6, P ¼ .03) (5). History of coronary
artery disease or peripheral artery disease did not predict
primary patency in two studies. Patient age and gender
did not affect primary patency in any of the studies.
Two studies assessed the association between metabolic
and inflammatory markers and primary patency. One
study showed that increased asymmetric dimethylarginine
and low-density lipoprotein significantly increased the risk
of primary patency loss (HR, 2.65, P ¼ .005, and HR,
2.29, P ¼ .03, respectively) (9). In another publication
from the same study, glycosylated hemoglobin (HbA1c)
4 7% was associated with shorter primary patency
compared with HbA1c o 7% (log-rank, P ¼ .01) (13).
Another study found that low albumin and increased
calcium phosphate product were associated with shorter
primary patency (RR, 0.32, P ¼ .001, and RR, 1.22, P ¼
.042, respectively) (16). One study investigated the
association between various inflammatory markers and
primary patency (Table 3) (9,13). None of the markers
were associated with primary patency.
Two studies assessed the association between medi-
cations and primary patency. One small study (N = 54)
found that calcium channel blockers improved patency
at 12 months (odds ratio, 5.1, P o .05) (17).
Assisted Primary Patency after
Intervention
Two studies assessed predictors of assisted primary
patency (Table 4). One study found that residualTable 4 . Factors Associated with Assisted Primary and Secondary P
Author, Year Variables Assessed Outcome
Mortamais et al,
2013 (18)
Patient age, gender, DM, RC
AVF position, AVF age,
immature AVF, lesion length
and location, stenosis before
and after angioplasty (%)
Assisted prim
patency
Heye et al, 2011 (7) Patient age, gender, AVF age
and location, prior AVF, DM,
lesion characteristics
Assisted prim
patency and
secondary
patency
Rajan et al, 2004 (8) Patient age, gender, AVF age
and location, DM, multiple
lesions
Secondary pa
Sugimoto et al,
2003 (19)
Patient age, gender, AVF age
and location, DM, multiple
lesions
Secondary pa
AVF ¼ arteriovenous fistula; DM ¼ diabetes mellitus; RC ¼ radiocepstenosis 450% after angioplasty was associated
with shorter assisted primary patency (RR, 2.92,
P ¼ .039) (18). In the other study, patient age 4 75
years predicted shorter assisted primary patency
compared with patient age 65–75 years (log-rank,
P ¼ .011) (7).
Secondary Patency after Intervention
Three studies assessed predictors of secondary patency
(Table 4). Increased patient age was associated with
secondary patency loss in two studies. Patient age 4 70
years shortened secondary patency in one study (log-
rank, P ¼ .029) (19). Patient age 4 75 years was
associated with shorter secondary patency in another
study (log-rank, P ¼ .014) (11). In the same study,
fistulas o 6 months old at angioplasty were associated
with shorter secondary patency compared with fistulas
6–12 months old and fistulas4 12 months old (log-rank,
P ¼ .037 and P ¼ .005, respectively). Two other studies
found no association between fistula age and secondary
patency (8,19).DISCUSSION
Our findings suggest that fistula and lesion character-
istics, such as newer fistulas and longer lesion length,
may be associated with primary patency loss after
balloon angioplasty. This association suggests that
hemodynamic shear stress and anatomic factors are the
most important determinants of restenosis (3). There are
fewer studies that assess the predictors of assisted pri-
mary and secondary patency; however, increased patient
age appears to be important and is possibly a reflection
of the quality of the peripheral vasculature.atency after Intervention
Significant Variables Effect Magnitude
ary Residual stenosis 450% after
angioplasty
RR, 2.92, P ¼ .04
ary Assisted primary patency
Patient age 4 75 y (vs 65–75 y) Not reported, P ¼ .01
Secondary patency
Patient age 4 75 y (vs 65–75 y) Not reported, P ¼ .01
AVF age o 6 mo (vs 6–12 mo
and 4 1 y)
Not reported, P ¼ .04
and P ¼ .005
tency None Not applicable
tency Patient age 4 70 y Log-rank, P ¼ .03
halic; RR ¼ relative risk.
Volume 25 ’ Number 6 ’ June ’ 2014 923Fistulas in which stenosis develops early after creation
are likely to be intrinsically faulty. Early dysfunction may
result from a diseased vein with preexisting pathology or
from a previously healthy vein that exhibits accelerated
neointimal hyperplasia in response to AVF creation. In
the latter case, it is unsurprising that restenosis occurs
sooner compared with AVFs that take longer for stenosis
to develop. The HR for the effect of fistula age as a
continuous measure was less powerful (15), suggesting
that the highest risk of reintervention is in fistulas
requiring angioplasty within 6 months of creation.
Higher flow rates and turbulent flow are likely to
explain observed shorter primary patency in upper arm
compared with forearm fistulas in one large study (8).
Longer lesions were associated with shorter primary
patency after angioplasty in two studies with significant
cutoff values of 2 cm and 4 cm (5,6). However, lesion
length was defined variably among studies, especially in
the presence of multiple lesions; either lesion length was
excluded (5), or longest and cumulative length was
reported (6,20). It is possible that lesion length is
important in more peripheral lesions (eg, juxtaanasto-
motic stenosis) but less influential in central lesions (eg,
cephalic arch stenosis), where extrinsic clavi-
pectoral fascia compression and the presence of valves
may limit vascular remodeling (21).
Although juxtaanastomotic and cephalic arch stenoses
are especially problematic (21,22), this review does not
provide any insights into the association between lesion
location and patency. Six studies analyzed lesion loca-
tion as a dichotomous variable, but classification of les-
ion location was different in each. Examples include
cephalic arch versus other (15), anastomosis versus other
(20), upper arm versus forearm (9), and juxtaana-
stomotic versus central veins (5). None of these were
significant, and so it is difficult to surmise the effect of
lesion location on patency.
Degree of stenosis before angioplasty was not asso-
ciated with patency outcomes in any study. This result is
probably due to the fact that the conventional definition
of stenosis expressed as a percentage is inaccurate in the
venous circuit because the adjacent vein may be small,
dilated after stenosis, or aneurysmal. Large differences in
degree of stenosis can be calculated depending on which
venous segment is used as a reference point (23).
Most studies found that diabetes was not associated
with patency after angioplasty. However, a previous
review of fistula patency (beginning from surgical creation)
concluded that diabetes was an important risk factor for
fistula dysfunction (24). Metabolic alterations associated
with diabetes may cause a prothrombotic environment,
endothelial dysfunction, and dysregulation of growth
factor, all predisposing to restenosis (13). Whether this
explanation is applicable to both the arterial and the
venous systems is unclear.
Although HbA1c4 7% was associated with restenosis
within 6 months in one study (13), this observation wasbased on log-rank test alone. HbA1c is an inaccurate tool
for accessing glycemic control in patients undergoing
hemodialysis owing to anemia, blood loss during dialy-
sis, reduced erythrocyte life span, and variable erythro-
poietin doses (25).
Systemic inflammation is likely to be less important
than hemodynamic factors in determining restenosis
after angioplasty. Although others have found that
baseline C-reactive protein predicts thrombosis events
in fistulas and grafts (26), two relatively large prospective
studies in this review found no association between
various inflammatory markers (Table 3) and primary
patency after intervention at 6 months.
Although there was some evidence for associations
between metabolic markers and primary patency after
angioplasty, their importance is unclear. Plasma asym-
metric dimethylarginine has been implicated in endothe-
lial dysfunction (27) and was shown to predict fistula
restenosis (9), but more studies are required. Venous
neointimal hyperplasia lacks lipid-laden foam cells and
other characteristics of arterial atherosclerosis, and the
association between low-density lipoprotein and primary
patency loss should not be interpreted as a causal
relationship.
Calcium channel blocker use was associated with
improved primary patency in one small study with signifi-
cant risk of bias. This finding was in contrast to the largest
study of medication use in patients undergoing dialysis, the
Dialysis Outcomes and Practice Patterns Study, which
found no association between medication use and unas-
sisted fistula patency (28). Angiotensin-converting enzyme
inhibitors were the only medication found to be associated
with prolonged cumulative fistula patency.
Our review was limited by bias in the design and
reporting of the studies we examined, and this precluded
formal data synthesis with meta-analysis. Despite this
limitation, we were able to describe explicitly potential
biases we found when appraising studies, permitting
readers to interpret our findings in the light of these
potential biases. Potential studies may have been missed
by our search strategy, which used only one database.
One reviewer performed the search and extracted data,
providing another source of potential error. Neverthe-
less, our summary presents the best current evidence that
exists to answer our research question.
Our review highlights the contentious and contra-
dictory evidence for risk factors for patency loss after
angioplasty, which is based largely on retrospective data.
There is a need for multicenter, prospective observatio-
nal studies, possibly in the form of a registry, to iden-
tify a set of predictors with an emphasis on modifiable
factors, such as the use of angiotensin-converting
enzyme inhibitors, to extend AVF patency after PTA.
Identifying predictors of patency after PTA can also
guide the testing and application of new endovascular
technology, such as cutting balloons (29), drug-eluting
balloons (30), and stent grafts (31).
Neuen et al ’ JVIR924 ’ Predictors of Patency after PTA in Hemodialysis FistulasIn conclusion, current evidence suggests that newer
fistulas and longer lesions may be associated with
reduced primary patency after angioplasty. These find-
ings are based on small observational studies of sub-
optimal quality. More large, well-designed, and well-
reported studies are needed to confirm these findings and
to guide the testing of new endovascular devices and
surgical techniques in randomized trials.REFERENCES
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